Krystal Biotech, Inc., began operations in April 2016. In March 2017, they converted from a California limited liability company to a Delaware C-corporation and changed its name from Krystal Biotech, LLC to Krystal Biotech, Inc. The company is a biotechnology company focused on the development and commercialization of genetic medicines for patients with rare diseases. Using their patented platform based on engineered HSV-1, they created vectors that can effectively deliver therapeutic transgenes to cells of interest in multi-organ systems. The cell's own machinery then transcribes and translates encoded effectors to treat or prevent disease. They are vectors for non-invasive or minimally invasive routes of administration in the office of a healthcare professional or possibly in the patient's home by a healthcare professional. Their goal is to develop easy-to-use drugs that can significantly improve the lives of patients with rare and chronic diseases.